Zhang Che, Tu Zi-Liang, Wang Qi-Bin, Cheng Xiao-Li, Zhang Peng-Hua
Yueyang Medical College, Shiyan 442000, China.
Yao Xue Xue Bao. 2007 Aug;42(8):843-8.
To study the effect of alpha1-acid glycoprotein 1 (ORM1) polymorphism on the concentration of free nortriptyline in serum, genotyping analysis was employed in ORM1 by sequencing. Eighteen unrelated male adults were chosen and given a single dose of 25 mg nortriptyline orally, then the blood samples were taken at 0, 1, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96 and 168 hours after drug administration. Nortriptyline and 10-OH-nortriptyline in serum and ultrafiltrate were detected for the total and free concentration by using HPLC-MS/MS. Pharmacokinetic parameters were compared among different ORM1 genotypes. No significant differences were shown in the pharmacokinetic parameters of total nortriptyline and 10-OH-nortriptyline. The mean AUC(0-infinity) of free nortritpyline in ORM1 * F/ * F1 subjects was significantly higher than that in ORM1 * F1/ * S and ORM1 * S/ * S subjects [(119.1 +/- 74.4) ng x mL(-1) x h vs (51.4 +/- 23.2) ng x mL(-1) x h and (42.4 +/- 11.6) ng x mL(-1) x h]. The percentage of protein binding in subjects with ORM1 * F1/ * F1 genotype at 2, 3, 4, 6, 8 and 12 h after administration was slightly lower than in those with ORM1 * F1/ * S and ORM1 * S/ * S genotypes while the distinct difference was shown at 4 h (P < 0.05). Different ORM1 genotypes might affect the protein binding percentage and the concentration of serum free nortriptyline. The ability binding to the drug was higher in subjects with ORM1 * S/ * S genotype than in those with other two genotypes, so as to cause the lower concentration of free nortriptyline.
为研究α1-酸性糖蛋白1(ORM1)基因多态性对血清中游离去甲替林浓度的影响,采用测序法对ORM1进行基因分型分析。选取18名无血缘关系的成年男性,口服单剂量25mg去甲替林,于给药后0、1、2、3、4、6、8、12、24、32、48、72、96和168小时采集血样。采用高效液相色谱-串联质谱法(HPLC-MS/MS)检测血清及超滤液中去甲替林和10-羟基去甲替林的总浓度和游离浓度。比较不同ORM1基因型的药代动力学参数。总去甲替林和10-羟基去甲替林的药代动力学参数无显著差异。ORM1 *F/*F1受试者游离去甲替林的平均AUC(0-∞)显著高于ORM1 *F1/*S和ORM1 *S/*S受试者[(119.1±74.4)ng·mL(-1)·h vs(51.4±23.2)ng·mL(-1)·h和(42.4±11.6)ng·mL(-1)·h]。给药后2、3、4、6、8和12小时,ORM1 *F1/*F1基因型受试者的蛋白结合率略低于ORM1 *F1/*S和ORM1 *S/*S基因型受试者,4小时时差异明显(P<0.05)。不同的ORM1基因型可能影响蛋白结合率和血清游离去甲替林浓度。ORM1 *S/*S基因型受试者与药物的结合能力高于其他两种基因型受试者,从而导致游离去甲替林浓度较低。